ABA	abatacept
ACPA	anti-cyclic citrullinated peptide antibodies
ACR	American College of Rheumatology
ADCC	antibody-dependent cellular cytotoxicity
Arg	arginine
bDMARDs	biologic disease-modifying antirheumatic drugs
BT	biological therapy
CRP	C-reactive protein
csDMARDs	conventional synthetic disease-modifying antirheumatic drugs
CTLA-4	cytotoxic T-lymphocyte-associated antigen 4
DAS28	28-joints Disease Activity Score
DMARDs	disease-modifying antirheumatic drugs
ESR	erythrocyte sedimentation rate
EULAR	European League Against Rheumatism
Fc	fragment crystallizable
FCGR	Fc-gamma receptor
GC	glucocorticoid
HAQ	Health Assessment Questionnaire score
His	histidine
HWE	Hardy–Weinberg equilibrium
IFX	infliximab
IgG1	human immunoglobulin G1
IV	intravenous
LDA	low-activity disease
LFN	leflunomide
MTX	methotrexate
NIJ	number of inflamed joints
NK	natural killer
NPJ	number of painful joints
OR	odds ratio
PCR	polymerase chain reaction
Phe	phenylalanine
PVAS	patient’s visual analogue scale
RA	rheumatoid arthritis
RF	rheumatoid factor
RTX	rituximab
SC	subcutaneous
SNP	single-nucleotide polymorphism
TCZ	tocilizumab
TNFi	tumor necrosis factor inhibitor
tsDMARDs	targeted synthetic disease-modifying antirheumatic drugs
Val	valine